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Abstract In multiple sclerosis (MS), a histopathological
distinction is made between different stages of white matter
(WM) lesions. These lesions are characterized as preactive,
active, chronic active or chronic inactive, depending on the
degree of microglia activation and degree of demyelina-
tion. The different lesions are not distinguishable on con-
ventional magnetic resonance imaging (MRI) scans at
standard clinical field strengths, but might be distinguished
using more advanced, quantitative MRI methods, such as
T1 relaxation time (T1-RT) mapping. To investigate this,
postmortem brain material from 20 MS patients was in-
vestigated, using both T1-RT MRI at 1.5T and histo-
pathology. The brain material contained a total of 9
preactive, 18 active, 30 chronic active and 14 chronic in-
active lesions, as well as 38 areas of normal appearing WM
(NAWM). Our results show that, at 1.5T, T1-RT qMRI can
only distinguish between categories NAWM/preactive,
active and chronic WM lesions. Advanced imaging at
standard field strengths, such as conventional imaging
measures, is therefore insufficient to differentiate the WM
lesions in MS, and higher field strengths may be required to
achieve better pathological differentiation of these lesions.
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Introduction
Multiple sclerosis (MS) is an inflammatory and demyeli-
nating disease of the central nervous system (CNS).
Pathologically, a distinction can be made between different
stages of white matter (WM) lesions that may be charac-
terized as preactive, active, chronic active or chronic in-
active, depending on their degree of microglia activation,
adaptive immune response and demyelination [1]. Preac-
tive lesions still have normal myelin density and mor-
phology, but already show clusters of activated microglia.
Active lesions show sharply bordered demyelination with
myelin-laden macrophages. In chronic active lesions,
macrophages have migrated to the rim of the lesion,
leaving the center fully demyelinated and hypocellular. In
chronic inactive lesions, there is complete demyelination;
microglia and macrophages are no longer present. Con-
ventional magnetic resonance imaging (MRI) techniques,
such as T2-weighted MRI, are highly sensitive to MS WM
lesions [2, 3] but do not provide information on the
aforementioned pathological heterogeneity. However, for
clinical purposes, it would be extremely useful if this
pathological distinction could be made in vivo. This way,
an inflammatory profile of MS patients could be more ac-
curately described; the clinical impact of these different
lesion stages, as well as their development over time, their
occurrence in different patient and disease stages and their
responsiveness to therapy could be monitored. Currently,
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the technique of choice for visualizing active inflammatory
WM lesions in vivo requires the administration of intra-
venous contrast agents. Quantitative MRI (qMRI) tech-
niques, such as quantitative T1 relaxation time (RT)
mapping, have shown to be both sensitive and more
pathologically specific [4–7]. T1-RT correlates with myelin
content and axonal count, which are both decreased in le-
sions compared to NAWM, and axonal count differs be-
tween different lesion stages [8, 9]. T1-RT mapping should
therefore have the potential to detect inflammatory lesions
at earlier stages and with more subtle pathology, which are
now only evident postmortem. Use of such advanced MRI
techniques could then improve clinical correlations of
MRI-detectable abnormalities in vivo, as these correlations
are generally low when using conventional techniques [10].
Therefore, the current study used advanced postmortem
MRI and histopathology correlation to investigate whether
T1-RT mapping can be used to distinguish the different
stages of WM demyelination in MS.
Methods
Patients and autopsy
Coronal brain sections of 20 patients with MS (11 females,
9 males, mean age at autopsy 63.6 ± 11.5 years, mean
disease duration 26.2 ± 15.3 years) were obtained after
rapid autopsy (mean postmortem delay 8 h 21 min).
Table 1 provides the demographic and neuropathological
details of the donors. Autopsy procedure and tissue sam-
pling followed the MS Center Amsterdam autopsy protocol
which has been described previously [11]. Briefly, for each
patient, five 10-mm-thick coronal hemispheric brain sec-
tions were cut and subjected to MR imaging. WM abnor-
malities visible on T2-weighted imaging were sampled.
MRI protocol and qMRI maps
The postmortem brain slices were scanned according to our
autopsy protocol [11, 12], using a whole body 1.5T mag-
netic resonance system (Sonata and Avanto, Siemens
Medical Systems, Erlangen, Germany) with a standard
circularly polarized head coil (Sonata) or a 12-channel
phased-array head coil (Avanto). Conventional Pd/T2-
weighted images were acquired (TR/TE1/TE2: 2500/85/
24 ms, in-plane resolution 0.5 mm 9 0.5 mm, slice
thickness 4 mm), centered in the middle of the slice and
parallel to the coronal surface. For T1 mapping, six sets of
images were acquired using a 3D gradient echo sequence
(3D-FLASH; TR/TE: 20/4 ms; in-plane resolution
1 mm 9 1 mm, slice thickness 4 mm), covering the same
volume as the Pd/T2-weighted images. Flip angles were 2,
5, 10, 15, 20 and 25, respectively. For B1-mapping,
five sets of images were acquired (TR/TE: 20/4 ms, in-
plane resolution 2 mm 9 2 mm, slice thickness 4 mm).
Flip angles were 140, 160, 180, 200 and 220,
respectively.
Image analysis
Pixel-by-pixel T1 calculations were performed with B1
correction as described by Venkatesan et al. [13]. Briefly,
B1 maps were generated from the image volumes with
nominal flip angles between 140 and 220 by determining
the ratio between the true and nominal flip angle from the
signal zero crossing that occurs at a true flip angle of 180.
Subsequently, T1 was determined for each pixel through a
nonlinear least squares fit by using the image and the cal-
culated B1 map [13].
Histopathology and immunohistochemistry
After MRI, the tissue blocks were fixed in 10 % formalin,
routinely processed and embedded in paraffin. Subse-
quently, 5 lm-thick sections were cut, mounted onto glass
slides (Superfrost, VWR international, Leuven, Belgium)
and dried overnight at 37 C. Sections were deparaffinized
in a series of xylene, 100 % ethanol, 96 % ethanol, 70 %
ethanol and water. Endogenous peroxidase activity was
blocked by incubating the sections in methanol with
0.3 % H2O2 for 30 min. After this, the sections were
rinsed with 0.01 mol/L phosphate-buffered saline (PBS,
pH 7.4). Staining and immunohistochemistry were per-
formed on adjacent sections with antibodies against the
following targets: microglia/macrophages (anti-HLA-DR,
clone LN3) and proteolipid protein (PLP; Serotec, Oxford,
UK). Bound primary antibodies were detected using
EnVision method (DAKOCytomation, Glostrup, Den-
mark) and 3,30diaminobenzidine-tetrahydrochloride dihy-
drate (DAB) was used as a chromogen. Sections were
counterstained with hematoxylin and mounted (Depex,
BDH; Poole, UK).
Scoring, classification and matching
WM lesions were scored by an experienced pathological
examiner (PvdV) and classified according to the van der
Valk and De Groot criteria [1] into preactive, active,
chronic active and chronic inactive lesions. Preactive le-
sions show myelin and clusters of activated microglia.
Active lesions show sharply bordered demyelination with
macrophages. Chronic active lesions show macrophages at
the rim of the lesion, and in chronic inactive lesions mi-
croglia and macrophages are no longer present. In total, 71
WM lesions were selected: 9 preactive, 18 active, 30
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chronic active and 14 chronic inactive lesions. Further-
more, 38 areas of normal appearing WM (NAWM) were
selected after histopathological inspection. Sections con-
taining WM lesions were matched to corresponding post-
mortem T2-weighted MR images as described previously
[12]; see Fig. 1 for an example. Lesions were outlined
(ROIs) on the T2 images using MIPAV software (Medical
Image Processing, Analysis and Visualization, National
Institutes of Health; mipav.cit.nih.gov). Subsequently,
ROIs were copied onto the T1 qMRI maps and T1-RT
values were obtained. ROIs were also placed in the
NAWN, so as to act as a control measurement. An average
T1-RT value was obtained over all voxels within a ROI
(lesion or NAWM). Then each lesional/NAWM T1-RT
value was assigned to their corresponding histopathological
group (preactive, active, chronic active, chronic inactive or
NAWM) and statistical analysis was performed. A flow-
chart of the autopsy, histological, matching and analyzing
procedure can be found in Fig. 2.
Statistical analysis
Descriptive and statistical analysis was performed using
SPSS 20.0 for windows (SPSS, Inc., Chicago, IL). For the
analysis between lesion types, we used the general
estimated equation (GEE) for related data (71 lesions from
20 patients; some lesions from the same patient and
therefore not independent). Scanner (Sonata or Avanto)
and lesion area (mm2) were added as covariates. Holm–
Bonferroni correction was used for multiple testing; sig-
nificance level was set at p\ 0.05.
Results
T1-RT increased consistently when moving from NAWM
through preactive and active lesions to chronic lesions.
Table 2 provides an overview of the mean (±SD) T1-RT
values of the different lesion types. Statistical analysis of
T1-RT revealed that NAWM differed significantly from
active, chronic active and chronic inactive lesion types (all
p\ 0.001). Preactive lesions also differed significantly
from active, chronic active and chronic inactive lesion
types (all p\ 0.001). However, NAWM and preactive le-
sions did not differ significantly from each other
(p = 0.742). Furthermore, active lesions differed sig-
nificantly from chronic inactive lesions (p\ 0.05), but not
from chronic active lesions (p = 0.286). Chronic active
and chronic inactive lesions did not differ significantly
from each other (p = 0.316). When lesion types were
Table 1 Demographic and neuropathology data of patients
Patient Sex Age DD (years) PMD (h:min) Scannera MS type Cause of death
1 F 44 8 10:15 1 PPMS Heart failure
2 M 63 24 7:05 1 SPMS Cardiac arrest
3 F 69 53 7:30 1 SPMS Heart failure
4 F 70 40 6:55 1 SPMS Urine tract infection
5 F 57 21 20:00 1 SPMS Decubitus
6 F 76 19 9:45 1 SPMS Unknown
7 F 81 64 4:00 1 SPMS Unknown
8 M 50 15 5:25 2 PPMS Pulmonary carcinoma
9 F 66 22 6:00 2 SPMS Unknown
10 M 49 24 8:00 2 SPMS Pneumonia
11 F 77 24 10:00 2 SPMS Euthanasia
12 M 72 23 7:55 2 SPMS Pneumonia
13 M 56 14 5:00 2 SPMS Cachexia
14 F 60 7 8:50 2 PPMS Euthanasia
15 M 54 12 8:15 2 PPMS Euthanasia
16 M 75 50 10:10 2 SPMS Pneumonia
17 F 50 17 7:35 2 SPMS Euthanasia
18 M 67 37 11:00 2 SPMS Heart failure
19 M 54 29 7:00 2 SPMS Euthanasia
20 F 81 21 6:30 2 PPMS Heart failure
Mean ± SD 63.6 ± 11.5 26.2 ± 15.3 8:21
PMD postmortem delay (h:min), DD disease duration in years since diagnosis
a Scanner; 1, Avanto; 2, Sonata
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grouped into three distinct groups, i.e., NAWM/preactive
(mean T1-RT = 798.32 ± 67.72 ms), active (mean T1-
RT = 1140.89 ± 204.82 ms) and chronic (mean T1-
RT = 1271.36 ± 231.19 ms, including chronic active and
chronic inactive lesions), all three groups differed sig-
nificantly from each other. In other words, NAWM/
Fig. 1 Matching of T2-w
image and T1 map with
histology. T2 image (a, e, i,
m) and T1 map (b, f, j, n) with a
red box indicating lesion
location. A preactive lesion (a–
d), an active lesion (e–h), a
chronic active lesion (i–l) and a
chronic inactive lesion (m–p).
Lesions are visualized by
histological sections of PLP (c,
g, k, o) and LN3 (d, h, l,
p) stainings. Note that outside
the brain slice, due to the virtual
absence of protons, T1-RT fits
give unreliable results.
However, to present un
unbiased view of our analysis,
we present the full data in the
T1-RT images in this figure.
The range for T1-RT maps is set
between 500 ms (black) and
1,500 ms (white)
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preactive lesions differed significantly from active
(p\ 0.05) and chronic lesions (p\ 0.001), and active le-
sions differed significantly from chronic lesions (p\ 0.05).
Discussion
In the current study, we set out to investigate whether the
different stages of WM demyelination that are defined in MS
histopathology can be differentiated by quantitative T1-RT
mapping. Upon analysis of the data, histopathologically
defined WM lesion types could be distinguished from
NAWM, and a distinction could also be made between the
overarching categories NAWM/preactive, active and
chronic lesions (including chronic active and chronic inac-
tive lesions). However, further subclassification into patho-
logical lesion types based on T1-RT measures was not
possible.
This means that, at a standard clinical field strength of
1.5T, there is additional value in distinguishing active
from chronic lesions, but determining which exact lesion
types are predominant in which patients or how specific
lesional stages correlate with clinical disability is still
limited and requires more research, possibly at higher field
strength with better signal-to-noise ratio and spatial
resolution. T1-RT measurement would still be an inter-
esting MRI candidate at higher field strength, as this
technique is highly sensitive to pathology and may detect
tissue abnormalities where other advanced MRI tech-
niques cannot [4]. This remains important when attempt-
ing to visualize subtle tissue pathology such as microglial
clustering or incipient demyelination. However, future
studies would probably benefit from combining T1-RT
with other advanced MRI measures, such as MTR or DTI,
as a combination of qMRI metrics with different patho-
logical substrates may increase pathological specificity
and hence improve MRI characterization of lesional
heterogeneity in MS.
A limitation of this study is that although from in vivo
measurements it is known that the accuracy and repro-
ducibility of the T1-RT mapping method used are accept-
able given the field strength [4, 13], we cannot fully
exclude that there may be T1-RT errors related specifically
to its application in fresh brain slices. Due to the rapid
autopsy setting, imaging time had to be minimized to
preserve tissue. Therefore, there was no time to perform a
direct quantification of any potential errors related
specifically to the application in fresh brain slices by, e.g.,
comparing to a trusted other technique such as inversion
recovery spin echo imaging with an array of inversion
times, because of the long acquisition times for such
techniques. Furthermore, our sample size was limited when
looking at the numbers of lesions within some of the lesion
categories. As a result, the power to detect differences
between, e.g., preactive and other types of lesions or
NAWM was a priori low. However, if lesion differentiation
can be improved by future (q)MRI efforts, a translation to
the in vivo setting would be highly interesting. Initially,
sensitivity and specificity of classifying lesions by qMRI,
or T1-RT in particular, would have to be determined.
Subsequently, an in vivo study with parameters similar to
those used in this postmortem study is recommended, to
see how T1-RT values change between the postmortem and
in vivo setting and how this affects classification. Lesional
changes may then be studied in vivo and in direct relation
Fig. 2 Flowchart of postmortem MRI with histology, matching and
analysis
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to clinical disability, and questions regarding homo- or
heterogeneity of lesional pathology within and between
patients [14, 15] as well as specific responses of lesions to
treatment could and should then be addressed.
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